Trial Profile
Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 31 May 2020 Results (n=35) of retrospective analysis assessing therapeutic response across treatment arms and different tumor location presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 10 Sep 2019 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the upcoming ESMO Asia Congress 2019 in Singapore on 22 November to 24 November.
- 21 Sep 2018 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO)